As Aventis digs its heels in and Sanofi refuses to raise its offer, a friendly deal between the two players looks increasingly less likely. Most observers still expect the deal to happen: white knight stories aren't convincing and none have the political support that this combination enjoys. But if Sanofi does win, it must use the transaction to transform its Franco-centric business, not merely enlarge it.
More than a month after Sanofi-Synthélabo launched its €48.3 billion ($60 billion) cash and stock hostile bid for compatriot Aventis SA , the battle isn't getting any less bloody, nor does it look like it's going to end soon [See Deal].
Sanofi's bid is inherently defensive. It knew that if it were unable to sign a deal before year-end 2004—and an...
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
